title: TECVAYLI速 plus DARZALEX FASPRO速 combination regimen significantly improves progression-free survival and overall survival versus standard of care
source: Yahoo
date: 2025-10-16
url: https://finnhub.io/api/news?id=c36a9d82a97e8a53b210ee66df8a6542745bcb97559b9f6af5d62d3c2ab18d16
Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI速 (teclistamab-cqyv) in combination with DARZALEX FASPRO速 (daratumumab and hyaluronidase-fihj) versus investigator's choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refract
